M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial
(MedPage Today) -- ML-007C-MA, an investigational muscarinic M1/M4 receptor agonist that combines betovumeline and fesoterodine fumarate, significantly improved schizophrenia symptoms in adults who had an acute exacerbation of psychosis, data from...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.